Bogumila Osekowska
Overview
Explore the profile of Bogumila Osekowska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Avivi I, Vesole D, Davila-Valls J, Usnarska-Zubkiewicz L, Olszewska-Szopa M, Milunovic V, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686635
Background: There is an increased risk of second primary malignancies (SMPs) in patients with multiple myeloma (MM). This multinational 'real-world' retrospective study analyzed the characteristics and outcomes of MM patients...
2.
Milczarek S, Kulig P, Zuchmanska A, Baumert B, Osekowska B, Bielikowicz A, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831679
The management of patients undergoing stem cell transplantation requires a multipurpose central venous catheter (CVC) to facilitate drug administration, parenteral nutrition, transfusion of blood products, and collection of blood samples....
3.
Milczarek S, Kulig P, Baumert B, Lanocha A, Sommerfeld K, Borowiecka E, et al.
Medicina (Kaunas)
. 2022 Oct;
58(10).
PMID: 36295511
We present an extremely rare case report of a 29-year-old multiple myeloma patient with central nervous system involvement and secondary hemophagocytic lymphohistiocytosis (HLH). We observed that HLH was presumably triggered...
4.
Sobus A, Baumert B, Golab-Janowska M, Kulig P, Paczkowska E, Luczkowska K, et al.
J Clin Med
. 2021 Nov;
10(22).
PMID: 34830531
ALS remains a fatal, neurodegenerative motor neuron disease. Numerous studies seem to confirm that innate immune system is involved in the pathophysiology of ALS. Hence, the assessment of the complement...
5.
Luczkowska K, Rutka M, Roginska D, Paczkowska E, Baumert B, Milczarek S, et al.
J Clin Med
. 2021 Oct;
10(19).
PMID: 34640602
The launch of novel chemotherapeutic agents-in particular, proteasome inhibitors and immunomodulatory drugs-dramatically changed multiple myeloma (MM) therapy, improving the response rate and prolonging progression-free survival. However, none of the anti-MM...
6.
Milczarek S, Baumert B, Sobus A, Wilk-Milczarek E, Sommerfeld K, Osekowska B, et al.
Medicina (Kaunas)
. 2021 Aug;
57(7).
PMID: 34357005
We present one of few cases of COVID-19 occurrence during the early phase of autologous hematopoietic stem cell transplantation. We observed an interesting correlation between the patient's rapid clinical deterioration...
7.
Wiacek M, Goslawski W, Grabowicz A, Sobus A, Kawa M, Baumert B, et al.
Stem Cells Int
. 2021 Jun;
2021:6631921.
PMID: 34122558
Background: Autologous bone marrow-derived lineage-negative (Lin-) cells present antiapoptotic and neuroprotective activity. The aim of the study was to evaluate the safety and efficacy of novel autologous Lin- cell therapy...
8.
Luczkowska K, Roginska D, Ulanczyk Z, Safranow K, Paczkowska E, Baumert B, et al.
Leuk Lymphoma
. 2021 Jun;
62(11):2768-2776.
PMID: 34092168
Multiple myeloma (MM) is a malignant, incurable neoplastic disease. The currently used treatment significantly improves the prognosis and extends the survival time of patients. Unfortunately, a common side effect of...
9.
Sobus A, Baumert B, Pawlukowska W, Golab-Janowska M, Paczkowska E, Welnicka A, et al.
Stem Cells Int
. 2020 Dec;
2020:8888271.
PMID: 33381192
Amyotrophic lateral sclerosis (ALS) remains a fatal, neurodegenerative disease frequently leading to dysarthria and impaired swallowing. Better understanding of ALS pathophysiology is prompting the use of humoral cell therapies. Hence,...
10.
Baumert B, Sobus A, Golab-Janowska M, Paczkowska E, Luczkowska K, Roginska D, et al.
Cells
. 2020 Aug;
9(8).
PMID: 32752182
Therapeutic interventions in amyotrophic lateral sclerosis (ALS) are still far from satisfying. Immune modulating procedures raise hopes for slowing the disease progression. Stem cell therapies are believed to possess the...